Edward Nash
Stock Analyst at Canaccord Genuity
(4.19)
# 497
Out of 5,111 analysts
73
Total ratings
56%
Success rate
14.05%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Edward Nash
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $526 → $587 | $554.57 | +5.85% | 12 | Nov 13, 2025 | |
| VKTX Viking Therapeutics | Maintains: Buy | $106 → $107 | $35.72 | +199.55% | 2 | Nov 12, 2025 | |
| VTYX Ventyx Biosciences | Maintains: Buy | $14 → $16 | $8.21 | +94.88% | 7 | Nov 7, 2025 | |
| SGMT Sagimet Biosciences | Maintains: Buy | $28 | $6.05 | +362.81% | 2 | Oct 2, 2025 | |
| IVA Inventiva | Maintains: Buy | $20 | $4.66 | +329.18% | 3 | Sep 30, 2025 | |
| CORT Corcept Therapeutics | Maintains: Buy | $140 | $81.12 | +72.58% | 10 | Sep 25, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $62 | $26.68 | +132.38% | 3 | Sep 17, 2025 | |
| TVTX Travere Therapeutics | Maintains: Buy | $45 → $47 | $35.85 | +31.10% | 10 | Apr 10, 2025 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $9 | $1.44 | +525.00% | 2 | Feb 26, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Hold | $4 | $1.25 | +220.00% | 2 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $89 | $74.78 | +19.02% | 1 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $8 | $1.04 | +669.23% | 3 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $17 | $2.02 | +741.58% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $3 → $2 | $3.08 | -35.06% | 4 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $900 → $180 | $0.98 | +18,271.10% | 2 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $82 | $34.34 | +138.79% | 6 | Jun 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $21.89 | +119.28% | 1 | May 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $650 | $5.00 | +12,900.00% | 1 | Nov 8, 2017 |
Madrigal Pharmaceuticals
Nov 13, 2025
Maintains: Buy
Price Target: $526 → $587
Current: $554.57
Upside: +5.85%
Viking Therapeutics
Nov 12, 2025
Maintains: Buy
Price Target: $106 → $107
Current: $35.72
Upside: +199.55%
Ventyx Biosciences
Nov 7, 2025
Maintains: Buy
Price Target: $14 → $16
Current: $8.21
Upside: +94.88%
Sagimet Biosciences
Oct 2, 2025
Maintains: Buy
Price Target: $28
Current: $6.05
Upside: +362.81%
Inventiva
Sep 30, 2025
Maintains: Buy
Price Target: $20
Current: $4.66
Upside: +329.18%
Corcept Therapeutics
Sep 25, 2025
Maintains: Buy
Price Target: $140
Current: $81.12
Upside: +72.58%
Celldex Therapeutics
Sep 17, 2025
Maintains: Buy
Price Target: $62
Current: $26.68
Upside: +132.38%
Travere Therapeutics
Apr 10, 2025
Maintains: Buy
Price Target: $45 → $47
Current: $35.85
Upside: +31.10%
Rani Therapeutics Holdings
Feb 26, 2025
Maintains: Buy
Price Target: $9
Current: $1.44
Upside: +525.00%
Pliant Therapeutics
Feb 10, 2025
Downgrades: Hold
Price Target: $4
Current: $1.25
Upside: +220.00%
Nov 25, 2024
Initiates: Buy
Price Target: $89
Current: $74.78
Upside: +19.02%
May 23, 2024
Maintains: Buy
Price Target: $6 → $8
Current: $1.04
Upside: +669.23%
May 19, 2023
Maintains: Buy
Price Target: $16 → $17
Current: $2.02
Upside: +741.58%
May 17, 2023
Maintains: Hold
Price Target: $3 → $2
Current: $3.08
Upside: -35.06%
Aug 8, 2022
Downgrades: Hold
Price Target: $900 → $180
Current: $0.98
Upside: +18,271.10%
Jun 19, 2020
Maintains: Buy
Price Target: $80 → $82
Current: $34.34
Upside: +138.79%
May 24, 2018
Initiates: Buy
Price Target: $48
Current: $21.89
Upside: +119.28%
Nov 8, 2017
Initiates: Buy
Price Target: $650
Current: $5.00
Upside: +12,900.00%